Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in Northern Thailand

Journal of the Medical Association of Thailand

Volumn 92, Issue 12, 2009, Pages 1597-1601

  Kuanprasert, Srun ^a   Dettrairat, Sakchai ^b   Palacajornsuk, Poonsub ^b   Kunachiwa, Warunee ^b   Phrommintikul, Arintaya ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Anticoagulant; Pharmacogenomics; Polymorphisms; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; WARFARIN;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNICITY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HAPLOTYPE; HOMOZYGOSITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PREVALENCE; PROTHROMBIN TIME; THAILAND; THROMBOEMBOLISM; VALVULAR HEART DISEASE;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; HEART VALVE DISEASES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MUTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PREVALENCE; RISK FACTORS; THAILAND; WARFARIN;

EID: 77249097871     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A, et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005; 5: 193-202.
2. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-33.
3. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5: 262-70.
4. FDA approves updated warfarin (coumadin) prescribing information [database on the Internet]. August 16 2007 [cited 2009 Sep 3]. Available from: http://www.fda.gov/bbs/topics/NEWS/2007/ NEW01684.html.
5. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116: 2563-70.
6. Oldenburg J, Watzka M, Rost S, Muller CR. VKORC1: molecular target of coumarins. J Thromb Haemost 2007; 5 (Suppl 1): 1-6.
7. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
8. Redman AR. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 2001; 21: 235-42.
9. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001; 51: 277-80.
10. Wang SL, Huang J, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5: 37-42.
11. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997; 7: 405-9.
12. Wiwanitkit V. Pharmacogenomic effect of cytochrome P450 2C9 polymorphisms in different populations. Clin Appl Thromb Hemost 2006; 12: 219-22.
13. Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998; 8: 365-73.
14. Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73: 253-63.
15. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
16. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9.
17. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 2004; 14: 539-47.
18. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, et al. Influence of coagulation factor,vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006; 79: 291-302.
19. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007; 121: 23-34.
20. Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 2006; 80: 346-55.